• Pharma, which used to cite the high cost of research, now say rebates within supply chain drive up prices.
  • Pharma says they don’t actually benefit much from list-price increases and that their net prices are suffering, because they are paying bigger rebates to pharmacy-benefit managers that negotiate prices in secret with their clients, such as employers and labor unions.
  • Drugmakers’ price increases are unrelated to the rebates, according to research commissioned by the Pharmaceutical Care Management Association, a trade group for PBMs.
  • Drug prices continue to fuel media stories and drive politicians to action but, for the most part, the real driver of high healthcare costs is being ignored.
  • The total percentage of non-elderly people with insurance and affordability problems to 26.2%.
  • The number of US adults with diabetes increased from 21.2 million in 2003-2004 to 30.2 million in 2013-2014, while the prevalence of obesity rose from 31.7% to 37.5% over the same period.
  • Millennials are on track to be the most obese generation.